Loading...

BBIO BRIDGEBIO PHARMA INC Investments/Divestments 8-K Filing

BRDG

BB

BRIDGEBIO PHARMA INC

(BBIO)

2024 8-K

Show Summary

Show Summary

Financial Statements

Management Changes

Financial Results

Financial Update

Q3 Financial Results

Gene Therapy Results

Joint Venture Formation

Financial Results

Appointment of President an...

Annual Meeting of Stockholders

Phase 2 Results Announcement

Financial Results

Underwriting Agreement for ...

License Agreement with Bayer

Financial Results

Funding Agreement for acora...

Presentation Update

Earnings Reports

Private Placement

Financial Results

Phase 3 Clinical Trial Results

Annual Meeting of Stockholders

Equity Distribution Agreement

Financial Results

Underwriting Agreement for ...

Positive Phase 2 results fo...

Financial Results and Manag...

External Links:

BridgeBio Pharma's subsidiaries entered into an exclusive license agreement with Bayer to develop and commercialize acoramidis for transthyretin amyloidosis in the European Union, with potential milestone payments and royalties.

AI Assistant

BRIDGEBIO PHARMA INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.